Amit Garg

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

Amit Garg, Joseph P. Balthasar · Journal of Pharmacokinetics and Pharmacodynamics · 2007 · 322 citations

Pharmacy, Pharmacokinetics, Physiology +9

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed et al. · The Lancet · 2024 · 164 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +3

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Rui‐Hua Xu, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2017 · 117 citations

Medicine, Oncology, Pharmacology +17

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

Amit Garg, Joseph P. Balthasar · The AAPS Journal · 2009 · 106 citations · Full text

Life Sciences, Immunology, Neuroscience +4

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Y-K Kang, Sun Young Rha, Pierfrancesco Tassone et al. · British Journal of Cancer · 2014 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17